Study Suggests Vaccine Increases Survival in Ovarian and Breast
Cancer Patients Following High-Dose Chemotherapy and Autologous
Stem Cell Transplant: Fred Hutchinson Cancer Research Center
Researcher Presents Results at American Society of Clinical Oncology
Meeting in Atlanta
[05/15/99; PR Newswire]
ATLANTA, May 15 /PRNewswire/ -- A new study suggests that the
administration of an experimental cancer vaccine following
autologous stem cell transplant can increase survival and
decrease relapse in ovarian and breast cancer patients when
compared to the stem cell transplant procedure alone. The data
was presented today at the 35th annual meeting of the American
Society of Clinical Oncology (ASCO) in Atlanta, May 15-18, 1999.
The research team at the Fred Hutchinson Cancer Research Center,
led by Leona Holmberg, M.D., Ph.D., and Brenda Sandmaier, M.D.,
treated 40 cancer patients (11 high-risk stage II/III breast,
22 stage IV breast and 7 stage III/IV ovarian) with
high-dose chemotherapy followed by autologous/syngeneic stem
cell transplantation. Twenty-six of the 40 patients also received
five doses of THERATOPE vaccine (STn-KLH), a therapeutic
vaccine being developed by Biomira, Inc. of Alberta, Canada
that induces the body's immune system to mount a response
against cancerous cells.
The full article can be found at:
http://biz.yahoo.com/prnews/990515/ga_biomira_1.html
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
